Kenya

Reimbursed Care Access

Kenya maintains a restrictive national control regime for narcotics and psychotropic substances under the Narcotic Drugs and Psychotropic Substances (Control) Act (Cap. 245), which broadly prohibits unauthorized possession, manufacture, trafficking and use of many classic psychedelics while preserving medical/regulated channels for legitimately recognized medicines. In practice, conventional psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are classified under the general narcotics/psychotropic controls and have no routine reimbursed medical access outside of approved clinical research; ketamine is the primary dissociative agent available within licensed medical settings and is subject to tight pharmacy/poisons controls. Reimbursement through public insurance for psychedelic therapies is effectively non‑existent; any clinical or compassionate use requires regulatory engagement with the Kenya Pharmacy and Poisons Board and is typically covered privately or funded through research/compassionate‑use mechanisms rather than national health insurance.